Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 7981397, 13 pages
http://dx.doi.org/10.1155/2016/7981397
Research Article

Synergic Effect of α-Mangostin on the Cytotoxicity of Cisplatin in a Cervical Cancer Model

1División de Investigación Básica, Instituto Nacional de Cancerología, Av. San Fernando #22, Apartado Postal 22026, Tlalpan, 14000 Mexico City, Mexico
2Facultad de Química, Universidad Nacional Autónoma de México, 04510 Mexico City, Mexico

Received 24 June 2016; Revised 3 November 2016; Accepted 8 November 2016

Academic Editor: Valentina Pallottini

Copyright © 2016 Jazmin M. Pérez-Rojas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Walboomers, M. V. Jacobs, M. M. Manos et al., “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” The Journal of Pathology, vol. 189, no. 1, pp. 12–19, 1999. View at Google Scholar
  2. Instituto Nacional de Estadística y Geografía, Día mundial contra el cáncer, [On line], http://www.inegi.org.mx/inegi/default.aspx?c=274.
  3. R. Fontanelli, G. Spatti, F. Raspagliesi, F. Zunino, and F. Di Re, “A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix,” Annals of Oncology, vol. 3, no. 2, pp. 117–121, 1992. View at Google Scholar · View at Scopus
  4. J. C. García-Ramos, R. Galindo-Murillo, F. Cortés-Guzmán, and L. Ruiz-Azuara, “Metal-based drug-DNA interactions,” Journal of the Mexican Chemical Society, vol. 57, no. 3, pp. 245–259, 2013. View at Google Scholar · View at Scopus
  5. S. Jaiman, A. K. Sharma, K. Singh, and D. Khanna, “Signalling mechanisms involved in renal pathological changes during cisplatin-induced nephropathy,” European Journal of Clinical Pharmacology, vol. 69, no. 11, pp. 1863–1874, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Cepeda, M. A. Fuertes, J. Castilla, C. Alonso, C. Quevedo, and J. M. Pérez, “Biochemical mechanisms of cisplatin cytotoxicity,” Anti-Cancer Agents in Medicinal Chemistry, vol. 7, no. 1, pp. 3–18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Fuertes, C. Alonso, and J. M. Pérez, “Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance,” Chemical Reviews, vol. 103, no. 3, pp. 645–662, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Pedraza-Chaverri, N. Cárdenas-Rodríguez, M. Orozco-Ibarra, and J. M. Pérez-Rojas, “Medicinal properties of mangosteen (Garcinia mangostana),” Food and Chemical Toxicology, vol. 46, no. 10, pp. 3227–3239, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Jindarat, “Xanthones from mangosteen (Garcinia mangostana): multi-targeting pharmacological properties,” Journal of the Medical Association of Thailand, vol. 97, no. S2, pp. S196–S201, 2014. View at Google Scholar · View at Scopus
  10. K. Uehara and M. Nagino, “Neoadjuvant treatment for locally advanced rectal cancer: a systematic review,” Surgery Today, vol. 46, no. 2, pp. 161–168, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Turner, L. Biganzoli, and A. Di Leo, “Continued value of adjuvant anthracyclines as treatment for early breast cancer,” The Lancet Oncology, vol. 16, no. 7, pp. e362–e369, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. A. F. A. Aisha, K. M. Abu-Salah, Z. Ismail, and A. Majid, “In vitro and in vivo anti-colon cancer effects of Garcinia mangostana xanthones extract,” BMC Complementary and Alternative Medicine, vol. 12, article 104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. J. J. Johnson, S. M. Petiwala, D. N. Syed et al., “α-Mangostin, a xanthone from mangosteen fruit, promotes cell cycle arrest in prostate cancer and decreases xenograft tumor growth,” Carcinogenesis, vol. 33, no. 2, pp. 413–419, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Sánchez-Pérez, R. Morales-Bárcenas, C. M. García-Cuellar et al., “The α-mangostin prevention on cisplatin-induced apoptotic death in LLC-PK1 cells is associated to an inhibition of ROS production and p53 induction,” Chemico-Biological Interactions, vol. 188, no. 1, pp. 144–150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. Pérez-Rojas, C. Cruz, P. García-López et al., “Renoprotection by α-mangostin is related to the attenuation in renal oxidative/nitrosative stress induced by cisplatin nephrotoxicity,” Free Radical Research, vol. 43, no. 11, pp. 1122–1132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Márquez-Valadez, P. D. Maldonado, S. Galván-Arzate et al., “Alpha-mangostin induces changes in glutathione levels associated with glutathione peroxidase activity in rat brain synaptosomes,” Nutritional Neuroscience, vol. 15, no. 5, pp. 13–19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. R. J. Tallarida, F. Porreca, and A. Cowan, “Statistical analysis of drug-drug and site-site interactions with isobolograms,” Life Sciences, vol. 45, no. 11, pp. 947–961, 1989. View at Publisher · View at Google Scholar · View at Scopus
  18. R. J. Tallarida, “Combination analysis,” Advances in Experimental Medicine and Biology, vol. 678, pp. 133–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. T.-C. Chou, “Drug combinations: from laboratory to practice,” Journal of Laboratory and Clinical Medicine, vol. 132, no. 1, pp. 6–8, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. T.-C. Chou, “Drug combination studies and their synergy quantification using the Chou-Talalay method,” Cancer Research, vol. 70, no. 2, pp. 440–446, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Gomes, E. Fernandes, and J. L. F. C. Lima, “Fluorescence probes used for detection of reactive oxygen species,” Journal of Biochemical and Biophysical Methods, vol. 65, no. 2-3, pp. 45–80, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Guide for the Care and Use of Laboratory Animals, The National Academies Press, 2010.
  23. M. Segovia-Mendoza, R. Jurado, R. Mir, L. A. Medina, H. Prado-Garcia, and P. Garcia-Lopez, “Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: In vitro and In vivo Study,” BMC Cancer, vol. 15, no. article 21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. L.-A. Medina, B.-I. Herrera-Penilla, M.-A. Castro-Morales et al., “Use of an orthovoltage X-ray treatment unit as a radiation research system in a small-animal cancer model,” Journal of Experimental & Clinical Cancer Research, vol. 27, no. 1, article 57, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. K. Smolev, D. S. Coffey, and W. W. Scott, “Experimental models for the study of prostatic adenocarcinoma,” Journal of Urology, vol. 118, no. 1, 1977. View at Google Scholar · View at Scopus
  26. T. W. Redding and A. V. Schally, “Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 10, pp. 6509–6512, 1981. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Yalamati, A. V. Bhongir, M. Karra, and S. R. Beedu, “Comparative analysis of urinary total proteins by bicinchoninic acid and pyrogallol red molybdate methods,” Journal of Clinical and Diagnostic Research, vol. 9, no. 8, pp. BC01–BC04, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Cetina, L. Rivera, J. Hinojosa et al., “Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results,” BMC Women's Health, vol. 6, article 3, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Vassbakk-Brovold, S. Berntsen, L. Fegran et al., “Individualized comprehensive lifestyle intervention in patients undergoing chemotherapy with curative or palliative intent: who participates?” PLoS ONE, vol. 10, no. 7, Article ID e0131355, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Díaz-Laviada and N. Rodríguez-Henche, “The potential antitumor effects of capsaicin,” Progress in Drug Research, vol. 68, pp. 181–208, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. J. G. Devassy, I. D. Nwachukwu, and P. J. H. Jones, “Curcumin and cancer: barriers to obtaining a health claim,” Nutrition Reviews, vol. 73, no. 3, pp. 155–165, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. C. K. Singh, M. A. Ndiaye, and N. Ahmad, “Resveratrol and cancer: challenges for clinical translation,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1852, no. 6, pp. 1178–1185, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Gajowik and M. M. Dobrzyńska, “Lycopene—antioxidant with radioprotective and anticancer properties. a review,” Roczniki Państwowego Zakładu Higieny, vol. 65, no. 4, pp. 263–271, 2014. View at Google Scholar · View at Scopus
  34. Y. A. Larasati, D. D. Pamungkas Putri, R. Y. Utomo, A. Hermawan, and E. Meiyanto, “Combination of cisplatin and cinnamon essential oil inhibits HeLa cells proliferation through cell cycle arrest,” Journal of Applied Pharmaceutical Science, vol. 4, no. 12, pp. 14–19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Arumuggam, N. A. Bhowmick, and H. P. V. Rupasinghe, “A review: phytochemicals targeting JAK/STAT signaling and IDO expression in cancer,” Phytotherapy Research, vol. 29, no. 6, pp. 805–817, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Matsumoto, Y. Akao, E. Kobayashi et al., “Induction of apoptosis by xanthones from mangosteen in human leukemia cell lines,” Journal of Natural Products, vol. 66, no. 8, pp. 1124–1127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Matsumoto, Y. Akao, H. Yi et al., “Preferential target is mitochondria in α-mangostin-induced apoptosis in human leukemia HL60 cells,” Bioorganic and Medicinal Chemistry, vol. 12, no. 22, pp. 5799–5806, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. J.-J. Chen, Z.-J. Long, D.-F. Xu et al., “Inhibition of autophagy augments the anticancer activity of α-mangostin in chronic myeloid leukemia cells,” Leukemia and Lymphoma, vol. 55, no. 3, pp. 628–638, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Nakagawa, M. Iinuma, T. Naoe, Y. Nozawa, and Y. Akao, “Characterized mechanism of α-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells,” Bioorganic and Medicinal Chemistry, vol. 15, no. 16, pp. 5620–5628, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Kurose, M.-A. Shibata, M. Iinuma, and Y. Otsuki, “Alterations in cell cycle and induction of apoptotic cell death in breast cancer cells treated with α-mangostin extracted from mangosteen pericarp,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 672428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Yasukawa, H. Fujihara, H. Fujimori et al., “Synergetic effects of PARP inhibitor AZD2281 and cisplatin in oral squamous cell carcinoma in Vitro and in Vivo,” International Journal of Molecular Sciences, vol. 17, no. 3, p. E272, 2016. View at Google Scholar
  42. M. Yasukawa, H. Fujihara, H. Fujimori et al., “Synergetic effects of PARP inhibitor AZD2281 and cisplatin in oral squamous cell carcinoma in vitro and in vivo,” International Journal of Molecular Sciences, vol. 17, no. 3, 2016. View at Google Scholar
  43. Y. Mizushina, I. Kuriyama, T. Nakahara, Y. Kawashima, and H. Yoshida, “Inhibitory effects of α-mangostin on mammalian DNA polymerase, topoisomerase, and human cancer cell proliferation,” Food and Chemical Toxicology, vol. 59, pp. 793–800, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Matsumoto, Y. Akao, K. Ohguchi et al., “Xanthones induce cell-cycle arrest and apoptosis in human colon cancer DLD-1 cells,” Bioorganic and Medicinal Chemistry, vol. 13, no. 21, pp. 6064–6069, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. F. A. Aisha, K. M. Abu-Salah, Z. Ismail, and A. M. S. A. Majid, “α-Mangostin enhances betulinic acid cytotoxicity and inhibits cisplatin cytotoxicity on HCT 116 colorectal carcinoma cells,” Molecules, vol. 17, no. 3, pp. 2939–2954, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Pedraza-Chaverrí, L. M. Reyes-Fermín, E. G. Nolasco-Amaya et al., “ROS scavenging capacity and neuroprotective effect of α-mangostin against 3-nitropropionic acid in cerebellar granule neurons,” Experimental and Toxicologic Pathology, vol. 61, no. 5, pp. 491–501, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. V. Somasundaram, R. Nadhan, K. Hemalatha, S. Kumar Sengodan, and P. Srinivas, “Nitric oxide and reactive oxygen species: clues to target oxidative damage repair defective breast cancers,” Critical Reviews in Oncology/Hematology, vol. 101, pp. 184–192, 2016. View at Publisher · View at Google Scholar
  48. B. Halliwell, “Dietary polyphenols: good, bad, or indifferent for your health?” Cardiovascular Research, vol. 73, no. 2, pp. 341–347, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. H. N. Lee, H. Y. Jang, H. J. Kim et al., “Antitumor and apoptosis-inducing effects of α-mangostin extracted from the pericarp of the mangosteen fruit (Garcinia mangostana L.) in YD-15 tongue mucoepidermoid carcinoma cells,” International Journal of Molecular Medicine, vol. 37, no. 4, pp. 939–948, 2016. View at Publisher · View at Google Scholar
  50. Q. Xu, J. Ma, J. Lei et al., “α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway,” BioMed Research International, vol. 2014, Article ID 546353, 12 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Sato, H. Fujiwara, H. Oku, K. Ishiguro, and Y. Ohizumi, “α-mangostin induces Ca2+-ATPase-dependent apoptosis via mitochondrial pathway in PC12 cells,” Journal of Pharmacological Sciences, vol. 95, no. 1, pp. 33–40, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Y. Ibrahim, N. M. Hashim, S. Mohan et al., “α-Mangostin from Cratoxylum arborescens demonstrates apoptogenesis in MCF-7 with regulation of NF-κB and Hsp70 protein modulation in vitro, and tumor reduction in vivo,” Drug Design, Development and Therapy, vol. 8, pp. 1629–1647, 2014. View at Publisher · View at Google Scholar · View at Scopus